| Name | Title | Contact Details |
|---|
OncoMed is a clinical development-stage biopharmaceutical company focused on discovering and developing first-in-class monoclonal antibody therapeutics targeting cancer stem cells, or CSCs. To date, we have advanced five novel anti-CSC product candidates into more than a dozen clinical studies and we continue to pursue the discovery of additional novel anti-cancer stem cell therapeutics. All of our product candidates were discovered internally in our own research laboratories. OncoMed’s discovery efforts focus on cancer stem cells, which are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs, also known as tumor-initiating cells, exhibit certain properties which include the capacity to divide and give rise to new CSCs via a process called self-renewal and the capacity to differentiate or change into the other cells that form the bulk of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for cancer recurrence and metastases. Our product candidates target CSCs pathways by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells. We believe our product candidates are distinct from current generations of chemotherapies and targeted therapies, and have the potential to significantly impact cancer treatment and the clinical outcome of patients with cancer. We utilize our proprietary technologies to (1) identify, isolate and evaluate CSCs, (2) identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation, and (3) develop targeted antibody and other protein-based therapeutics that are designed to modulate cancer stem cell targets and inhibit the growth of CSCs. These targets are in pathways implicated in cancer biology and stem cell biology. Our current clinical and preclinical product candidates address targets in the Notch, Wnt and RSPO pathways, as well as other undisclosed fundamental CSC pathways.
Deep Expertise, Broad Reach Versiti is a strategic affiliation of successful healthcare organizations whose vision is to improve the health of patients as the national leader in innovative transfusion solutions for healthcare systems. Everyone in our nation’s healthcare system is seeking new and better ways to provide high-quality patient care at an affordable cost. Organizations that offer vital resources must also look at new models of operating that will continually improve patient outcomes, increase the quality of service, and reduce the cost of healthcare. Working together, Versiti offers hospitals a more comprehensive range of services, including transfusion medicine, transplantation, stem cell and cellular therapies, hematology, oncology and genomics. We are passionate about improving the lives of our patients and hospital partners. We apply our deep expertise in blood-related service to solve the toughest challenges Our expertise and resources lead to new products, solutions and services to meet patient and hospital needs. We Believe: By bringing together the industry’s best and brightest, the depth and breadth of our expertise sets us apart Our relationships with donors, patients and hospital partners inspire everything we do We offer best-in-class products and services Our work sets new standards for quality, efficiency and care Our approach will reshape our industry and create new ways to help people and communities thrive
Quest Diagnostics Nichols Institute is a Chantilly, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Microbe Inotech Labs Inc is a Bridgeton, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Research Testing Laboratories, Inc. is a Great Neck, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.